Advancements in NAST, such as human epidermal growth factor receptor 2 (HER2)-targeted therapy or immune-check point blockade, have increased the pathologic complete response (pCR) rate, even in patients with locally advanced breast cancer [4–6]. Here, ERBB2 is linked to breast carcinoma.